Super Session Nodal and Metastatic Disease– The Ever-Evolving Battlefront

Sunday, May 10, 2026

8:00 AM - 8:45 AM ET

Co-Moderator(s)

George Chang, MD, MS, MHCM (he/him/his)

Associate Vice President and Professor
University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

All of the relevant financial relationships listed below have been mitigated.
This individual has no relevant relationships with ineligible companies.
Maria Widmar, MD, MPH (she/her/hers)

Assistant Attending
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical Center
New York, New York, United States

All of the relevant financial relationships listed below have been mitigated.
This individual has no relevant relationships with ineligible companies.

CME: .75 hours

Self-

Assessment: .75 hours

Surgery remains the cornerstone of curative treatment for colorectal cancer. Patients with locally advanced or metastatic disease present unique management challenges for the colorectal surgeon. Curative intent resection includes complete, en bloc resection of the primary tumor along with any involved adjacent organs and complete resection of the associated lymph node distribution. For patients with metastases, surgical resection remains the primary treatment with curative potential. However, the role of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal metastasis continues to evolve. This symposium will review the latest evidence-based management for patients with

1) Locally advanced colon cancer and the optimal approach to central mesenteric and beyond central mesenteric lymph node metastases
2) Rectal cancer with lateral pelvic lymph node metastasis
3) Colorectal cancer patients at risk or diagnosed with peritoneal metastasis

Learning Objectives:

Upon completion of this activity, participants should be able to:

Recognize the anatomical and oncologic rationale for extended mesenteric and lymph node dissection in colon cancer surgery, identify cases warranting more aggressive approaches, and evaluate current evidence and techniques (including D1–D3 dissections, central vascular ligation, and CME) to optimize oncologic outcomes.
Review indications, oncologic impact, and technical considerations of lateral pelvic lymph node dissection (LPLND) in rectal cancer to guide optimal patient selection and multidisciplinary treatment planning. .
Identify appropriate candidates and optimal timing for surgical management of colorectal cancer with peritoneal metastasis, recognize the role of CRS and HIPEC, and evaluate current evidence to guide patient selection, operative planning, and treatment sequencing.

Presentations:

8:00 AM - 8:05 AM ET

Introduction
8:05 AM - 8:15 AM ET

Chasing Nodes and Mesentery in Colon Cancer—How Far for a Complete Cure?
Faculty: Ramy Behman, MD PhD – Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center
8:15 AM - 8:25 AM ET

Lateral Pelvic Nodes in Rectal Cancer: When (and Why) to Resect
Faculty: Hye-Jin Kim, MD – Kyungpook National University Chilgok Hospital
8:25 AM - 8:35 AM ET

Peritoneal Metastasis in CRC: Who, When, and How to Act
Faculty: Miguel Pera, MD PhD – Hospital Clinic Barcelona